v3.26.1
Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Tables)
6 Months Ended
Jun. 30, 2026
Accounting Policies [Abstract]  
Research and Development Expense for Major Programs
The following table sets forth significant research and development (“R&D”) expenses by program as regularly provided to the CODM (in thousands):

Three Months Ended 
June 30,
Six Months Ended 
June 30,
2026202520262025
Birtamimab (NEOD001)
$(70)$19,433 $(39)$45,347 
PRX012
2,261 15,093 7,614 33,168 
PRX019
1,231 1,824 3,358 3,926 
Other R&D
5,376 4,167 10,492 8,887 
Total R&D
$8,798 $40,517 $21,425 $91,328